Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2008

01-10-2008 | Research Articles

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Authors: Alfonso Sánchez-Muñoz, Ana María García-Tapiador, Esther Martínez-Ortega, Rosario Dueñas-García, Ana Jaén-Morago, Ana Laura Ortega-Granados, Mónica Fernández-Navarro, Capilla de la Torre-Cabrera, Basilio Dueñas, Ana Isabel Rueda, Francisco Morales, César Ramírez-Torosa, María Dolores Martín-Salvago, Pedro Sánchez-Rovira

Published in: Clinical and Translational Oncology | Issue 10/2008

Login to get access
Metadata
Title
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
Authors
Alfonso Sánchez-Muñoz
Ana María García-Tapiador
Esther Martínez-Ortega
Rosario Dueñas-García
Ana Jaén-Morago
Ana Laura Ortega-Granados
Mónica Fernández-Navarro
Capilla de la Torre-Cabrera
Basilio Dueñas
Ana Isabel Rueda
Francisco Morales
César Ramírez-Torosa
María Dolores Martín-Salvago
Pedro Sánchez-Rovira
Publication date
01-10-2008
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2008
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-008-0265-y

Other articles of this Issue 10/2008

Clinical and Translational Oncology 10/2008 Go to the issue

Educational Series

In silico analysis of protein neoplastic biomarkers for cervix and uterine cancer

Case Reports

Endotracheal metastases from colon adenocarcinoma

Brief Research Articles

Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results

Research Articles

Sensitivity to change of the Spanish validated Memorial Pain Assessment Card in cancer patients

Educational Series

Genetic modelling of the PTEN/AKT pathway in cancer research

Editorial

Reasons for the New Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits